2 results about "Therapeutic targeting" patented technology

The application belongs to the technical field of biological medicine, and discloses a spinal cord injury treatment drug based on a LINC00311 / miR-4318 / MYLK regulation axis and an application thereof, and aims to solve the technical problems of poor targeting and large side effects of the existing anti-inflammatory treatment of spinal cord injury. The effective component of the drug is an inhibitor of LINC00311, the inhibitor is selected from one or more of shRNA, siRNA, antisense oligonucleotide and CRISPRi system, can target the specific nucleotide sequence of LINC00311, and can be used in combination with miR-4318 mimic, and is administered by intrathecal injection, slow virus carrier delivery and the like. The in-vitro experiment proves that the inhibitor can significantly inhibit the release of TNF-alpha, IL-1beta, IL-6 and other pro-inflammatory factors by microglia cells; the in-vivo experiment shows that it can significantly improve the BBB motor function score of spinal cord injury rats, and reduce spinal cord tissue edema and necrosis. The application first discloses the mechanism of the LINC00311 / miR-4318 / MYLK ceRNA regulation axis in spinal cord injury, has the advantages of novel target, significant effect and high transformation potential, and provides a new scheme for the clinical treatment of spinal cord injury.

This invention relates to the field of bone repair materials technology, and discloses a bone repair material utilizing deer bone peptides and its preparation method. The method includes the preparation of deer bone extract, the preparation of melon seed extract, the formulation of a composite peptide solution, the preparation of a carrier base solution, and the compounding and molding. By using a composite peptide solution containing deer bone peptides and melon seed peptides, the synergistic effect of the two peptides enables the material to possess excellent osteoblast proliferation, differentiation, and anti-inflammatory activity, thereby promoting the repair and regeneration of bone defects and enhancing the bioactivity and therapeutic targeting of the material. By mixing the composite peptide solution with a carrier base solution containing a biocompatible carrier material and adding a cross-linking agent for cross-linking, a stable structure is formed between the peptides and the carrier material, thereby ensuring that the material has good mechanical support properties and a controllable degradation rate, ensuring that the material maintains its morphology in the early stages of implantation and guides new bone growth in an orderly manner over time.